

Authorizations and Appeals Guide for ZEPOSIA® (ozanimod)

INDICATIONS

ZEPOSIA® (ozanimod) is indicated for the treatment of:

1. Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
2. Moderately to severely active ulcerative colitis (UC) in adults.

IMPORTANT SAFETY INFORMATION

Contraindications:

- Patients who in the last 6 months, experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure or have a presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker
- Patients with severe untreated sleep apnea
- Patients taking a monoamine oxidase (MAO) inhibitor

Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.

Guide Overview

At Bristol-Myers Squibb (BMS) Company, we believe patient support can be a critical component of accessibility, affordability, and adherence. Once the prescriber has decided to prescribe ZEPOSIA® (ozanimod), ZEPOSIA 360 Support™ is ready to help patients navigate the multiple sclerosis (MS) and ulcerative colitis (UC) treatment journeys.

BMS created this guide to support patients in navigating:



Authorizations



Appeals



**Patient Support
and Resources**



For additional information or patient-specific assistance, please contact ZEPOSIA 360 Support™ at 1-833-ZEPOSIA (1-833-937-6742).

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider (HCP) and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Table of Contents

› ZEPOSIA® (ozanimod) Indications and Important Safety Information

› ZEPOSIA 360 Support™

› Getting Started With ZEPOSIA

- › HCP Office Checklists
- › Enrolling Your Patient in ZEPOSIA 360 Support™
- › Baseline Assessments
- › ZEPOSIA Starter Kit

› Coverage and Access to ZEPOSIA

- › Coverage Scenarios
- › Prior Authorization Checklist
- › Navigating Formulary Exceptions and Appeals
- › ZEPOSIA Bridge Program

› Multiple Sclerosis Template Letters

- › Supporting Information
- › Letter of Medical Necessity for Patients Not Actively on Treatment
- › Letter of Medical Necessity for Patients Currently on Treatment
- › Step Therapy Letter
- › Formulary Exception Letter
- › Letter of Appeal for Patients Not Actively on Treatment
- › Letter of Appeal for Patients Currently on Treatment

› Ulcerative Colitis Template Letters

- › Supporting Information
- › Letter of Medical Necessity for Patients Not Actively on Treatment
- › Letter of Medical Necessity for Patients Currently on Treatment
- › Step Therapy Letter
- › Formulary Exception Letter
- › Letter of Appeal for Patients Not Actively on Treatment
- › Letter of Appeal for Patients Currently on Treatment

› Patient Financial Support



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



ZEPOSIA® (ozanimod)

Indications and Important Safety Information



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



ZEPOSIA® (ozanimod)

Indications and Important Safety Information

INDICATIONS

ZEPOSIA® (ozanimod) is indicated for the treatment of:

1. Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
2. Moderately to severely active ulcerative colitis (UC) in adults.

IMPORTANT SAFETY INFORMATION

Contraindications:

- Patients who in the last 6 months, experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure or have a presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker
- Patients with severe untreated sleep apnea
- Patients taking a monoamine oxidase (MAO) inhibitor

Infections: ZEPOSIA may increase the susceptibility to infections. Life-threatening and rare fatal infections have occurred in patients receiving ZEPOSIA. Obtain a recent (i.e., within 6 months or after discontinuation of prior MS or UC therapy) complete blood count (CBC) including lymphocyte count before initiation of ZEPOSIA. Delay initiation of ZEPOSIA in patients with an active infection until the infection is resolved. Consider interruption of treatment with ZEPOSIA if a patient develops a serious infection. Continue monitoring for infections up to 3 months after discontinuing ZEPOSIA.

- Herpes zoster and herpes simplex were seen in clinical trials of ZEPOSIA. Herpes simplex encephalitis and varicella zoster meningitis have been reported with sphingosine 1-phosphate (S1P) receptor modulators. Patients without a healthcare professional-confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus (VZV), should be tested for antibodies to VZV before initiating ZEPOSIA.

- Cases of fatal cryptococcal meningitis (CM) and disseminated cryptococcal infections have been reported with S1P receptor modulators. If CM is suspected, ZEPOSIA should be suspended until cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated.
- In the MS and UC clinical studies, patients who received ZEPOSIA were not to receive concomitant treatment with antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatment of MS and UC. Concomitant use of ZEPOSIA with any of these therapies would be expected to increase the risk of immunosuppression. When switching to ZEPOSIA from immunosuppressive medications, consider the duration of their effects and their mode of action to avoid unintended additive immunosuppressive effects.
- Use of live attenuated vaccines should be avoided during and for 3 months after treatment with ZEPOSIA. If live attenuated vaccine immunizations are required, administer at least 1 month prior to initiation of ZEPOSIA.

Progressive Multifocal Leukoencephalopathy (PML): PML is an opportunistic viral infection of the brain that typically occurs in patients who are immunocompromised, and that usually leads to death or severe disability.

PML has been reported in patients treated with S1P receptor modulators, including ZEPOSIA, and other MS and UC therapies and has been associated with some risk factors (e.g., immunocompromised patients,



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



ZEPOSIA® (ozanimod) Important Safety Information (cont.)

polytherapy with immunosuppressants, duration of use). Based on data from patients with MS, longer treatment duration increases the risk of PML in patients treated with S1P receptor modulators, and the majority of PML cases have occurred in patients treated with S1P receptor modulators for at least 18 months. If PML is suspected, withhold ZEPOSIA and perform an appropriate diagnostic evaluation. If confirmed, treatment with ZEPOSIA should be discontinued.

Immune reconstitution inflammatory syndrome (IRIS) has been reported in MS patients treated with S1P receptor modulators who developed PML and subsequently discontinued treatment. IRIS presents as a clinical decline in the patient's condition that may be rapid, can lead to serious neurological complications or death, and is often associated with characteristic changes on MRI. The time to onset of IRIS in patients with PML was generally within a few months after S1P receptor modulator discontinuation. Monitoring for development of IRIS and appropriate treatment of the associated inflammation should be undertaken.

Bradyarrhythmia and Atrioventricular Conduction Delays: Since initiation of ZEPOSIA may result in a transient decrease in heart rate and atrioventricular conduction delays, dose titration is recommended to help reduce cardiac effects. If treatment with ZEPOSIA is considered, advice from a cardiologist should be sought for those individuals:

- with significant QT prolongation
- with arrhythmias requiring treatment with Class 1a or III anti-arrhythmic drugs
- with ischemic heart disease, heart failure, history of cardiac arrest or myocardial infarction, cerebrovascular disease, and uncontrolled hypertension
- with a history of Mobitz type II second-degree or higher AV block, sick sinus syndrome, or sino-atrial heart block

Liver Injury: Clinically significant liver injury, including acute liver failure requiring transplant, has occurred in patients treated with ZEPOSIA in the postmarketing setting. Signs of liver injury, including elevated serum

hepatic enzymes and elevated total bilirubin, have occurred as early as ten days after the first dose. Obtain transaminase and bilirubin levels, if not recently available (i.e., within 6 months), before initiation of ZEPOSIA. Obtain transaminase levels and total bilirubin levels periodically during treatment and until two months after ZEPOSIA discontinuation. Patients should be monitored for signs and symptoms of any hepatic injury. Patients who develop symptoms suggestive of hepatic dysfunction should have hepatic enzymes promptly checked, and ZEPOSIA should be interrupted. Treatment should not be resumed if a plausible alternative etiology for the signs and symptoms cannot be established, because these patients are at risk for severe drug-induced liver injury.

Fetal Risk: There are no adequate and well-controlled studies in pregnant women. Based on animal studies, ZEPOSIA may cause fetal harm. Women of childbearing potential should use effective contraception to avoid pregnancy during treatment and for 3 months after stopping ZEPOSIA. Women who become pregnant while taking ZEPOSIA for MS may enroll in the ZEPOSIA pregnancy registry by calling 1-877-301-9314 or visiting www.zeposiapregnancyregistry.com.

Increased Blood Pressure: Increase in systolic pressure was observed after about 3 months of treatment and persisted throughout treatment. Blood pressure should be monitored during treatment and managed appropriately.

Respiratory Effects: ZEPOSIA may cause a decline in pulmonary function. Spirometric evaluation of respiratory function should be performed during therapy, if clinically indicated.

Macular Edema: S1P modulators have been associated with an increased risk of macular edema. Obtain a baseline evaluation of the fundus, including a macula, near the start of treatment with ZEPOSIA. Perform an examination of the fundus, including the macula, periodically while on therapy and any time there is a change in vision. Continuation of ZEPOSIA therapy in patients with macular edema has not been evaluated. Macular edema over an extended period of time (i.e. 6 months) can lead to permanent visual loss. Consider discontinuing ZEPOSIA if



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



ZEPOSIA® (ozanimod) Important Safety Information (cont.)

macular edema develops. The risk of recurrence after rechallenge has not been evaluated.

Patients with a history of uveitis and patients with a history of diabetes mellitus are at increased risk of macular edema during ZEPOSIA therapy.

Cutaneous Malignancies: The risk of cutaneous malignancies (including basal cell carcinoma, squamous cell carcinoma, and melanoma) is increased in patients treated with S1P receptor modulators. Skin examinations are recommended prior to or shortly after the start of treatment and periodically thereafter for all patients, particularly those with risk factors for skin cancer. Providers and patients are advised to monitor for suspicious skin lesions. If a suspicious skin lesion is observed, it should be promptly evaluated. As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using sunscreen with a high protection factor. Concomitant phototherapy with UV-B radiation or PUVA photochemotherapy is not recommended in patients taking ZEPOSIA.

Posterior Reversible Encephalopathy Syndrome (PRES): Rare cases of PRES have been reported in patients receiving a S1P receptor modulator. If a ZEPOSIA-treated patient develops unexpected neurological or psychiatric symptoms or any symptom/sign suggestive of an increase in intracranial pressure, a complete physical and neurological examination should be conducted. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, treatment with ZEPOSIA should be discontinued.

Unintended Additive Immunosuppressive Effects From Prior Immunosuppressive or Immune-Modulating Drugs: When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.

Severe Increase in Multiple Sclerosis (MS) Disability After Stopping ZEPOSIA:

In MS, severe exacerbation of disease, including disease rebound, has been rarely reported after discontinuation of a S1P receptor modulator. The possibility of severe exacerbation of disease should be considered after stopping ZEPOSIA treatment so patients should be monitored upon discontinuation. After stopping ZEPOSIA in the setting of PML, monitor for development of immune reconstitution inflammatory syndrome (PML-IRIS).

Immune System Effects After Stopping ZEPOSIA: After discontinuing ZEPOSIA, the median time for lymphocyte counts to return to the normal range was 30 days, with approximately 80% to 90% of patients in the normal range within 3 months. Use of immunosuppressants within this period may lead to an additive effect on the immune system, therefore caution should be applied when initiating other drugs 4 weeks after the last dose of ZEPOSIA.

Most Common Adverse Reactions that occurred in the MS clinical trials of ZEPOSIA-treated patients ($\geq 4\%$): upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension.

In the UC clinical trials, the most common adverse reactions that occurred in $\geq 4\%$ of ZEPOSIA-treated patients and greater than in patients who received placebo were upper respiratory infection, liver test increased, and headache.

Use in Specific Populations: Hepatic Impairment: Dosage adjustment in patients with mild or moderate hepatic impairment (Child-Pugh class A or B) is required, and use of ZEPOSIA in patients with severe hepatic impairment (Child-Pugh class C) is not recommended.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



ZEPOSIA 360 Support™



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



For patients prescribed ZEPOSIA® (ozanimod)

ZEPOSIA 360 Support™ to Help Patients Begin Therapy



The **covermymeds®** portal serves as a central location to manage and track your patients' access to ZEPOSIA and allows you to:

- › Enroll patients and request services using the digital Start Form. Start Forms can also be submitted via fax
- › Track patient status through the cases tab
- › Submit prior authorizations (PAs)



In-home, nationwide baseline assessments with scheduling and appointments available **7 days per week including evenings** for eligible, commercially insured patients



For new, eligible patients enrolled in ZEPOSIA 360 Support™, a free **28-dose supply of ZEPOSIA** is available through the **Starter Kit**



Eligible, commercially insured patients may receive up to **2 years of ZEPOSIA through the Bridge Program** if there is a delay or denial in coverage



Eligible, commercially insured patients may pay as little as **\$0 in out-of-pocket costs per prescription**, subject to a maximum benefit during a calendar year



Local, dedicated support through your Access and Reimbursement Manager (ARM) and team of Support Coordinators^a

For complete terms and conditions for the services listed above, please see www.zeposia.com/terms-conditions.

^aZEPOSIA Support Coordinators can provide general information about ZEPOSIA 360 Support™ but cannot provide medical advice.



Please see Important Safety Information on pages **5-7** and **full Prescribing Information** and **Medication Guide** at www.ZEPOSIAhcp.com.

IMPORTANT
SAFETY
INFORMATION

ZEPOSIA
360 SUPPORT™

GETTING
STARTED

COVERAGE
AND ACCESS

MS TEMPLATE
LETTERS

UC TEMPLATE
LETTERS

PATIENT
FINANCIAL
SUPPORT



Getting Started With ZEPOSIA® (ozanimod)



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Checklist: Accessing ZEPOSIA® (ozanimod) Through **covermymeds**®

- ☐ Enroll your patient in ZEPOSIA 360 Support™ electronically through **covermymeds**®
 - › If the patient is unable to sign via the CoverMyMeds portal in-office at the time of the Start Form submission, **covermymeds**® will reach out via email to collect the signature
- ☐ Advise your patient to save the ZEPOSIA 360 Support™ phone number in their phone **1-833-937-6742**
- ☐ Complete required **baseline assessments**
 - › If baseline assessment assistance was requested on the Start Form, review the results of the baseline assessments and provide clearance in the **covermymeds**® portal or upload the baseline assessment **clearance form**
 - For complete terms and conditions, please see **www.zeposia.com/terms-conditions**.
- ☐ If required, submit a PA through **covermymeds**®
- ☐ Follow up on the status of your patient's case by visiting the cases tab in the **covermymeds**® portal

**Contact ZEPOSIA
360 Support™**



Call us at **1-833-ZEPOSIA (1-833-937-6742)**
Monday – Friday, 8 AM – 8 PM ET
(translation services available)



Visit
www.ZEPOSIAhcp.com



Please see Important Safety Information on pages **5-7** and **full Prescribing Information** and **Medication Guide** at **www.ZEPOSIAhcp.com**.



Checklist: Accessing ZEPOSIA® (ozanimod) by Fax

- ☐ Enroll your patient in ZEPOSIA 360 Support™ by faxing the Start Form to **1-833-727-7701**
 - › Before faxing, ensure the patient has signed the Start Form in office or by visiting [ZEPOSIA.com/esign](https://www.ZEPOSIA.com/esign)
- ☐ Advise your patient to save the ZEPOSIA 360 Support™ phone number in their phone **1-833-937-6742**
- ☐ Complete required **baseline assessments**
 - › If assistance was requested on the Start Form, submit the baseline assessment **clearance form** to ZEPOSIA 360 Support™
 - › You may also review the baseline assessment results and provide clearance in the **covermy meds®** portalFor complete terms and conditions, please see www.zeposia.com/terms-conditions.
- ☐ If required, submit a PA through **covermy meds®** or directly to the patient's insurance
- ☐ Follow up on the status of your patient's case by visiting the cases tab in the **covermy meds®** portal

Contact ZEPOSIA
360 Support™



Call us at **1-833-ZEPOSIA (1-833-937-6742)**
Monday – Friday, 8 AM – 8 PM ET
(translation services available)



Visit
www.ZEPOSIAhcp.com



Please see Important Safety Information on pages **5-7** and **full Prescribing Information** and **Medication Guide** at www.ZEPOSIAhcp.com.



Enrolling Your Patient in ZEPOSIA 360 Support™

Access the ZEPOSIA 360 Support™ Start Form through **covermy meds**® or the [HCP website](#).

Ensure the Start Form includes the patient or patient representative signature. eSignatures may be provided in the **covermy meds® portal at [ZEPOSIA.com/esign](https://www.ZEPOSIA.com/esign).**

Advise your patient to save the ZEPOSIA 360 Support™ Support Coordinator^a phone number **1-833-937-6742** in their phone.

Enroll in ZEPOSIA 360 Support™ by submitting the Start Form



Enroll online at
covermy meds®



Fax the signed
Start Form to
1-833-727-7701

**If you need assistance,
our support team is
happy to help**



Call us at **1-833-ZEPOSIA (1-833-937-6742)**
Monday – Friday, 8 AM – 8 PM ET
(translation services available)



Visit
www.ZEPOSIAhcp.com

^aZEPOSIA Support Coordinators can provide general information about ZEPOSIA 360 Support™ but cannot provide medical advice.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Cases Tab in the covermymeds® Portal

The screenshot shows the 'covermymeds®' portal interface. On the left is a sidebar with 'REQUESTS' and 'CASES' tabs. The 'CASES' tab is active. The main area has a search bar with the text 'Search by patient name or date of birth (ex: 12/31/1980)'. Below the search bar are buttons for 'START NEW' and 'ENTER KEY'. A table lists two cases:

Patient Name	Case Key	DOB	RX	Enrollment Status	Prior Auth. Status	Action Required
Jane Doe	E-123DEF	01/01/1981	BRAND X	Complete	New (Not Sent to Plan)	Prior Authorization
Jonathan Doe	K-123VIG	3/12/1976	BRAND X	Not Started	Sent to Plan	Enrollment Form

View the status of all of your patient cases and see detailed information including action items for each case in the cases tab.

The screenshot shows the detailed view of a case for Jane Doe (CASE KEY E-123DEF, D.O.B. 01/01/1981, Brand X 20MG). The interface includes a sidebar with 'REQUESTS' and 'CASES' tabs. The 'CASES' tab is active. The main area displays the following information:

- SPECIALTY PHARMACY:** Dispensing Pharmacy will be displayed upon transfer of prescription to the dispensing pharmacy.
- ADDITIONAL SUPPORT:** Brand X Website, Diagnosis Foundation.
- YOUR TASKS:**
 - Enrollment Form: Complete (VIEW)
 - Prior Authorization: New (Not Sent to Plan) (START)
- PATIENT SERVICES TASKS:**
 - Benefit Verification/Investigation: Complete (VIEW)
 - Prior Authorization Support: Not Started
 - Appeal Support: Not Started
 - Financial Assistance Enrollment: Not Started
 - Coordinate Order Fulfillment: Not Started



Baseline Assessments

Prior to First Dose

- › **Electrocardiogram (ECG) to detect preexisting conduction abnormalities**
- › **Blood work (within the past 6 months)**
 - Complete blood count (CBC), including lymphocyte count
 - Transaminase and bilirubin levels
- › **Determine varicella zoster virus (VZV) history and vaccination status^a and evaluate medication history**

Periodically obtain transaminase and total bilirubin levels.^b

These assessments are not intended to make suggestions about the efficacy, safety, or indication of use for the product. For complete ZEPOSIA 360 Support™ terms and conditions, please see www.zeposia.com/terms-conditions.

^aVZV vaccination of antibody-negative patients is recommended prior to commencing treatment. Without documentation of VZV/chicken pox or documentation of a full course of vaccination, test for antibodies. If live attenuated immunizations are required, administer at least 1 month prior to initiation.

^bDuring treatment and until two months after discontinuation.

^cSIP receptor modulators, including ZEPOSIA, have been associated with an increased risk of macular edema. Perform an examination of the fundus, including the macula, periodically while on therapy and any time there is a change in vision.

^dAlso obtain a skin examination periodically during treatment, particularly for patients with risk factors for skin cancer. Providers and patients are advised to monitor for suspicious skin lesions, which should be promptly evaluated if observed.

Before or Shortly After Initiation


- › **Ophthalmic evaluation** of the fundus, including the macula^c
- › **Skin examination^d**

Check to see if your patients recently completed, or plan to have, an annual skin or eye exam to satisfy these requirements.

Periodically monitor for changes in vision^c and suspicious skin lesions.^d

Affordability Matters

Eligible, commercially insured patients may receive assistance with reimbursement for out-of-pocket costs for assessments listed above.



If baseline assessment assistance is requested on the Start Form, the prescriber must review assessment results and provide clearance for the patient to start therapy. Submit the baseline assessment [clearance form](#) by fax **1-833-727-7701** or provide clearance through [covermymeds®](#).



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Baseline Assessments May Be Completed in Your Office or in the Patient's Home



In-office

Commercially insured patients may be reimbursed for out-of-pocket costs associated with required assessments, subject to a maximum benefit during a calendar year.

To request reimbursement, contact **ZEPOSIA 360 Support™** at **1-833-ZEPOSIA**.



In-home

Patients may receive baseline assessments in their home,^{a,b} administered by a medical technician. The patient's insurance will not be billed, and the patient will not be responsible for any out-of-pocket costs.



In-home, nationwide baseline assessments with scheduling and appointments available **7 days per week including evenings** for eligible, commercially insured patients.

Please see page **15** for a complete list of baseline assessments

For complete terms and conditions, please see www.zeposia.com/terms-conditions.

^aAll in-home assessments will need to be completed prior to initiation.

^bSkin exams are not available in-home and should be scheduled separately with an HCP. Eligible, commercially insured patients may receive assistance with skin exam out-of-pocket costs through ZEPOSIA 360 Support™.



Please see Important Safety Information on pages **5-7** and **full Prescribing Information** and **Medication Guide** at www.ZEPOSIAhcp.com.



ZEPOSIA® (ozanimod) Starter Kit

For new, eligible patients enrolled in ZEPOSIA 360 Support™, a free **28-dose supply of ZEPOSIA** is available through the **Starter Kit**.

You may request a Starter Kit for your patient by selecting the appropriate box on the **Start Form**.

In order to receive a Starter Kit, the patient must be prescribed ZEPOSIA for an FDA-approved indication, must not be receiving a 28-dose sample from your office, and the Start Form must be submitted directly to ZEPOSIA 360 Support™.

For complete terms and conditions, please see www.zeposia.com/terms-conditions.

ZEPOSIA Starter Kit

7-day Starter Pack

A blister pack with 7 capsules for the 7-day, dose-titration period



21-dose bottle

21 capsules of the maintenance dose (0.92 mg)



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.

IMPORTANT
SAFETY
INFORMATION

ZEPOSIA
360 SUPPORT™

GETTING
STARTED

COVERAGE
AND ACCESS

MS TEMPLATE
LETTERS

UC TEMPLATE
LETTERS

PATIENT
FINANCIAL
SUPPORT



Coverage and Access to ZEPOSIA® (ozanimod)



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Coverage Scenarios

ZEPOSIA 360 Support™ will complete a benefit verification to determine your patient's coverage and out-of-pocket costs for ZEPOSIA® (ozanimod). Benefit verification results will be faxed to your office and available through the [covermymeds](#)® portal. Results may note that your patient's insurance requires additional information based on one of the coverage scenarios outlined below.

1

COVERED: Prior authorization required

Payer requires an authorization to obtain:

- Additional information about your patient's diagnosis and medical history
- Clinical rationale for the course of treatment
- Confirmation of prescription by a specialist



Tip: Review the PA checklist on page [20](#) and template letters of medical necessity for MS on pages [25-26](#) and for UC on pages [33-34](#).

2

COVERED: Step therapy required

Payer may require your patient to try and fail 1 or more therapies prior to approving coverage for ZEPOSIA



Tip: More than half of all US states have enacted laws to address step therapy requirements.

For additional information on your state, contact your ARM team. Review the step therapy template letter for MS on page [27](#) and for UC on page [35](#).

3

NOT COVERED: Formulary exception may be available

If ZEPOSIA is not covered because it is not listed on the payer's formulary, you or your patient may be able to request a formulary exception



Tip: For additional information on formulary exceptions, please see page [21](#) and a formulary exception template letter for MS on page [28](#) and for UC on page [36](#).

US – United States.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Prior Authorization (PA) Checklist

Important PA considerations

covermymeds® offers electronic prior authorization (ePA) support including submission and tracking of ePAs.

Review the PA requirements for your patient's plan and the submission options.



Tip: Many plans have a PA request form available on their websites. Be sure you use the correct form for the patient's health plan. Payers may also have multiple versions of forms for different plans (eg, Medicare Advantage vs private commercial offering).

If the PA form is general and doesn't include rationale for treatment and a summary of the patient's diagnosis and history, you may consider submitting a letter of medical necessity and/or supporting medical information.

Where to find information

If you have enrolled your patient in ZEPOSIA 360 Support™, the program will send you PA requirements. For additional information, contact ZEPOSIA 360 Support™ or your patient's health insurance plan.

You can call the plan or visit their website to review PA submission options. ZEPOSIA 360 Support™ can also assist with this process.



Tip: If you determine that the authorization request is urgent or requires expedited review, consider noting this on the top of the request.

Package configuration	Tablet strength	NDC number
Bottles of 30	0.92 mg ozanimod	59572-820-30
7-day Starter Pack	7-capsule Starter Pack containing: (4) 0.23 mg ozanimod capsules and (3) 0.46 mg ozanimod capsules	59572-810-07
Starter Kit (7-day Starter Pack and 0.92 mg 21-count bottle)	28-capsule Starter Kit including: one 7-capsule Starter Pack containing: (4) 0.23 mg ozanimod capsules and (3) 0.46 mg ozanimod capsules and one bottle containing: (21) 0.92 mg ozanimod capsules	59572-890-28 59572-890-07 59572-890-21

NDC – National Drug Code.

If your patient will be receiving a free ZEPOSIA® (ozanimod) Starter Kit, PA is required for the maintenance dose only.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Navigating Exceptions and Appeals

Navigating formulary exceptions

An exception may be requested to obtain a product that is not included in a plan's formulary or to request removal of a utilization management requirement for a formulary product, such as:



Step therapy requirement not met



Product is non-preferred



Quantity limit exceeded

Navigating appeal requests

If a coverage determination for ZEPOSIA® (ozanimod) is unfavorable, the treating HCP or patient may submit an appeal. Consider the following:



Ensure the appeal is organized and clearly written with supporting clinical information



Provide clinical rationale as to why the preferred product is not appropriate for the patient



If an appeal is denied, a peer-to-peer review may be available. For additional information, contact ZEPOSIA 360 Support™

Refer to the health plan's specific guidelines for additional information.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Bridge Program


BMS is committed to making ZEPOSIA® (ozanimod) accessible to appropriate patients. Eligible, commercially insured patients may receive up to 2 years of ZEPOSIA through the Bridge Program if there is a delay or denial in coverage.

In order for patients to remain eligible for the Bridge Program, you must complete these steps:



For complete terms and conditions, please see www.zeposia.com/terms-conditions.

**If you need assistance,
our support team is
happy to help**



Call us at **1-833-ZEPOSIA (1-833-937-6742)**
Monday – Friday, 8 AM – 8 PM ET
(translation services available)



Visit
www.ZEPOSIAhcp.com



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



MS Template Letters



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



MS Supporting Information

The example templates in this section may be used to support requests for access to ZEPOSIA® (ozanimod). The letters should be submitted with relevant medical records, on your practice's letterhead, and signed by the prescriber.

The following supporting information may be included within the letters:

Disease summary may include the following if applicable

- Relapse history and/or description of patient's relapsing multiple sclerosis (RMS) symptoms and symptom progression
- Magnetic resonance imaging (MRI) scan documentation and findings (eg, brain lesions)
- Neurological exam findings
- RMS overview. Include Expanded Disability Status Scale (EDSS) score, if available
- Intolerable side effects due to alternate RMS therapies
- Past drugs and treatments that were tried and failed
- Activities of daily living affected by current RMS disease
- Clinical trial data that may be relevant to the patient's treatment
- Other relevant medical information
- ZEPOSIA requires baseline assessments. For additional information, please see page [15](#) of this guide or go to the [HCP website](#)

Treatment plan

- The treatment plan should include the dosage and treatment escalation schedule, as appropriate

Additional documentation

- Denial letter
- [Prescribing Information](#)
- [Food and Drug Administration \(FDA\) approval letter](#)
- Clinical practice guidelines
- Clinical notes and medical records

The information provided in the template letters is for informational purposes for patients who have been prescribed ZEPOSIA. These template letters are not intended to substitute for a prescriber's independent clinical decision making.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



MS Letter of Medical Necessity for Patients Not Actively on Treatment

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

Name: [Patient's Name]
DOB: [XX/XX/XXXX]
Patient Policy ID Number: [Policy ID #]
Reference Number: [Reference #]
Date(s) of Service: [XX/XX/XXXX]

Re: Letter of Medical Necessity for ZEPOSIA® (ozanimod)

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request coverage for ZEPOSIA® (ozanimod) for the treatment of [diagnosis], *International Classification of Diseases, 10th Revision, Clinical Modification* diagnosis code [diagnosis code]. I have reviewed your drug coverage policy and believe that the appropriate treatment decision at this time is to initiate treatment with ZEPOSIA. This letter provides the clinical rationale and relevant information about the patient's medical history.

ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration in 2020 for the treatment of adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is the rationale for prescribing ZEPOSIA based on my patient's disease summary.

[Insert disease summary]

I am requesting this coverage because [insert reason(s) for medical necessity]. Please see attached documents to support my clinical findings.

Considering the patient's history and condition, I believe treatment with ZEPOSIA is medically necessary for my patient. Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Enclosures: [List and attach additional documents to support your treatment rationale]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



MS Letter of Medical Necessity for Patients Currently on Treatment

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

Name: [Patient's Name]
DOB: [XX/XX/XXXX]
Patient Policy ID Number: [Policy ID #]
Reference Number: [Reference #]
Date(s) of Service: [XX/XX/XXXX]

Re: Letter of Medical Necessity for ZEPOSIA® (ozanimod)

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request coverage for ZEPOSIA® (ozanimod) for the treatment of [diagnosis], *International Classification of Diseases, 10th Revision, Clinical Modification* diagnosis code [diagnosis code]. I have reviewed your drug coverage policy and believe that the appropriate treatment decision at this time is to discontinue [current drug name] and initiate treatment with ZEPOSIA. This letter provides the clinical rationale and relevant information about the patient's medical history and treatment.

ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration in 2020 for the treatment of adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is the rationale for prescribing ZEPOSIA based on my patient's disease summary.

[Insert disease summary]

I am requesting this coverage because [insert reason(s) for medical necessity]. Please see attached documents to support my clinical findings.

Considering the patient's history and condition, I believe treatment with ZEPOSIA is medically necessary for my patient. Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Enclosures: [List and attach additional documents to support your treatment rationale]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



MS Step Therapy Letter

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

[Patient's Name]
[Date of Birth]
Patient Policy ID Number: [ID #]
Reference Number: [# if available]
Date(s) of Service: [XX/XX/XXXX]

Re: Letter Requesting Approval for Use of ZEPOSIA® (ozanimod) Capsules

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request coverage for ZEPOSIA® (ozanimod), for the treatment of [diagnosis], ICD-10-CM diagnosis code [diagnosis code]. ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration (FDA) in 2020 for the treatment of adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

I have reviewed your drug coverage policy and believe that the appropriate treatment decision at this time is to initiate treatment with ZEPOSIA. This letter outlines the patient's medical history and previous treatments (if applicable) that support my recommendation for ZEPOSIA as the appropriate treatment option.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is a rationale for prescribing ZEPOSIA based on my patient's disease summary.

- [Insert disease summary eg, relapse history and/or description of patient's RMS disease progression, magnetic resonance imaging (MRI) scan documentation and findings, Expanded Disability Status Scale (EDSS) score, if available.]
- [If appropriate, insert past drugs and treatments that were tried and failed and patient's response to these therapies (eg, intolerable side effects to alternate RMS therapies).]
- [Brief description of the patient's recent conditions, and any other patient characteristics or relevant clinical considerations.]

I have prescribed ZEPOSIA and am requesting this coverage because of the following rationale:

- [Please provide clinical rationale for treatment.]
- [If applicable, please provide additional supporting information (eg, patient-specific data, information from the ZEPOSIA Prescribing Information, clinical trial data that may be relevant to the patient's treatment, and/or clinical peer-reviewed literature).]
- [If applicable, provide appropriate state step-therapy legislation evidence, include statute (if available).]

Considering the patient's history and condition, I believe treatment with ZEPOSIA is the appropriate option for my patient. Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



MS Formulary Exception Letter

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

Name: [Patient's Name]
DOB: [XX/XX/XXXX]
Patient Policy ID Number: [Policy ID #]
Reference Number: [Reference #]
Date(s) of Service: [XX/XX/XXXX]

Re: Request for Formulary Exception for ZEPOSIA® (ozanimod)

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request coverage for ZEPOSIA® (ozanimod) for the treatment of [diagnosis], *International Classification of Diseases, 10th Revision, Clinical Modification* diagnosis code [diagnosis code]. Your reason[s] for the denial [is/are] [reason(s)].

Currently, ZEPOSIA is not on your formulary; however, I am requesting an exception for ZEPOSIA to be available as a preferred drug and ask that any applicable National Drug Code blocks be removed so a prescription for my patient may be filled.

ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration in 2020 for the treatment of adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is the rationale for prescribing ZEPOSIA based on my patient's disease summary.

[Insert disease summary]

I am requesting this exception because [insert reasons]. Considering the patient's history and condition, I believe treatment with ZEPOSIA is medically necessary for my patient.

Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Enclosures: [List and attach additional documents to support your treatment rationale]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



MS Letter of Appeal for Patients Not Actively on Treatment

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

Name: [Patient's Name]

DOB: [XX/XX/XXXX]

Patient Policy ID Number: [Policy ID #]

Reference Number: [Reference #]

Date(s) of Service: [XX/XX/XXXX]

Re: Letter of Appeal for ZEPOSIA® (ozanimod)

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request reconsideration of your denial of coverage for ZEPOSIA® (ozanimod) for the treatment of [diagnosis], *International Classification of Diseases, 10th Revision, Clinical Modification* (ICD-10-CM) diagnosis code [diagnosis code]. Your reason[s] for the denial [is/are] [reason(s)].

Based on my experience with treating patients with [diagnosis], ICD-10-CM diagnosis code [diagnosis code], and the patient's condition and medical history, I believe treatment with ZEPOSIA is appropriate and medically necessary. This letter provides the clinical rationale and relevant information about the patient's medical history and treatment.

ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration in 2020 for the treatment of adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is the rationale for prescribing ZEPOSIA based on my patient's disease summary.

[Insert disease summary]

[Supporting information as requested by the plan in the denial letter]

This is my [level of request] prior authorization appeal. A copy of the [level of denial] denial letter is included along with medical notes in response to the denial. Considering the patient's history and condition, I believe treatment with ZEPOSIA is medically necessary for my patient.

Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Enclosures: [List and attach additional documents to support your treatment rationale]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



MS Letter of Appeal for Patients Currently on Treatment

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

Name: [Patient's Name]

DOB: [XX/XX/XXXX]

Patient Policy ID Number: [Policy ID #]

Reference Number: [Reference #]

Date(s) of Service: [XX/XX/XXXX]

Re: Letter of Appeal for ZEPOSIA® (ozanimod)

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request reconsideration of your denial of coverage for ZEPOSIA® (ozanimod) for the treatment of [diagnosis], *International Classification of Diseases, 10th Revision, Clinical Modification* (ICD-10-CM) diagnosis code [diagnosis code]. Your reason[s] for the denial [is/are] [reason(s)].

Based on my experience with treating patients with [diagnosis], ICD-10-CM diagnosis code [diagnosis code], and the patient's condition and medical history, I believe treatment with [current drug name] should be discontinued and replaced with ZEPOSIA as it is appropriate and medically necessary. This letter provides the clinical rationale and relevant information about the patient's medical history and treatment.

ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration in 2020 for the treatment of adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is the rationale for prescribing ZEPOSIA based on my patient's disease summary.

[Insert disease summary]

[Supporting information as requested by the plan in the denial letter]

This is my [level of request] prior authorization appeal. A copy of the [level of denial] denial letter is included along with medical notes in response to the denial. Considering the patient's history and condition, I believe treatment with ZEPOSIA is medically necessary for my patient.

Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Enclosures: [List and attach additional documents to support your treatment rationale]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



UC Template Letters



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



UC Supporting Information

The example templates in this section may be used to support requests for access to ZEPOSIA® (ozanimod). The letters should be submitted with relevant medical records, on your practice's letterhead, and signed by the prescriber.

The following supporting information may be included within the letters:

Disease summary may include the following if applicable

- Patient's diagnosis, condition, and history
- Previous therapies used to treat UC and the patient's response to those therapies
- Description of the patient's recent symptoms
- Documentation of required baseline assessments
- Other relevant medical information

Treatment plan

- The treatment plan should include the dosage and treatment escalation schedule, as appropriate

Additional documentation

- Denial letter
- [Prescribing Information](#)
- [Food and Drug Administration \(FDA\) approval letter](#)
- Clinical practice guidelines
- Clinical notes and medical records

The information provided in the template letters is for informational purposes for patients who have been prescribed ZEPOSIA. These template letters are not intended to substitute for a prescriber's independent clinical decision making.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



UC Letter of Medical Necessity for Patients Not Actively on Treatment

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

Name: [Patient's Name]
DOB: [XX/XX/XXXX]
Patient Policy ID Number: [Policy ID #]
Reference Number: [Reference #]
Date(s) of Service: [XX/XX/XXXX]

Re: Letter of Medical Necessity for ZEPOSIA® (ozanimod)

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request coverage for ZEPOSIA® (ozanimod) for the treatment of [diagnosis], *International Classification of Diseases, 10th Revision, Clinical Modification* diagnosis code [diagnosis code]. I have reviewed your drug coverage policy and believe that the appropriate treatment decision at this time is to initiate treatment with ZEPOSIA. This letter provides the clinical rationale and relevant information about the patient's medical history.

ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration in 2021 for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is the rationale for prescribing ZEPOSIA based on my patient's disease summary.

[Insert disease summary]

I am requesting this coverage because [insert reason(s) for medical necessity]. Please see attached documents to support my clinical findings.

Considering the patient's history and condition, I believe treatment with ZEPOSIA is medically necessary for my patient. Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Enclosures: [List and attach additional documents to support your treatment rationale]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



UC Letter of Medical Necessity for Patients Currently on Treatment

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

Name: [Patient's Name]
DOB: [XX/XX/XXXX]
Patient Policy ID Number: [Policy ID #]
Reference Number: [Reference #]
Date(s) of Service: [XX/XX/XXXX]

Re: Letter of Medical Necessity for ZEPOSIA® (ozanimod)

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request coverage for ZEPOSIA® (ozanimod) for the treatment of [diagnosis], *International Classification of Diseases, 10th Revision, Clinical Modification* diagnosis code [diagnosis code]. I have reviewed your drug coverage policy and believe that the appropriate treatment decision at this time is to discontinue [current drug name] and initiate treatment with ZEPOSIA. This letter provides the clinical rationale and relevant information about the patient's medical history and treatment.

ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration in 2021 for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is the rationale for prescribing ZEPOSIA based on my patient's disease summary.

[Insert disease summary]

I am requesting this coverage because [insert reason(s) for medical necessity]. Please see attached documents to support my clinical findings.

Considering the patient's history and condition, I believe treatment with ZEPOSIA is medically necessary for my patient. Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Enclosures: [List and attach additional documents to support your treatment rationale]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



UC Step Therapy Letter

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

[Patient's Name]
[Date of Birth]
Patient Policy ID Number: [ID #]
Reference Number: [# if available]
[Dates of Service]

Re: Letter Requesting Approval for Use of ZEPOSIA® (ozanimod) Capsules

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request coverage for ZEPOSIA® (ozanimod), for the treatment of [diagnosis], ICD-10-CM diagnosis code [diagnosis code]. ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration (FDA) in 2021 for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

I have reviewed your drug coverage requirement and believe that the appropriate treatment decision at this time is to initiate treatment with ZEPOSIA. This letter outlines the patient's medical history and previous treatments (if applicable) that support my recommendation for ZEPOSIA as the appropriate treatment option.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is a rationale for prescribing ZEPOSIA based on my patient's disease summary.

- [Insert disease summary]
- [If appropriate, insert past drugs and treatments that were tried and failed and patient's response to these therapies (eg, intolerable side effects).]
- [Brief description of the patient's recent conditions, and any other patient characteristics or relevant clinical considerations]

I have prescribed ZEPOSIA, and am requesting this coverage because of the following rationale:

- [Please provide clinical rationale for treatment]
- [If applicable, please provide additional supporting information (eg, patient-specific data, information from the ZEPOSIA Prescribing Information, clinical trial data that may be relevant to the patient's treatment, and/or clinical peer-reviewed literature)]
- [If applicable, provide appropriate state step-therapy legislation evidence, include statute (if available)]

Considering the patient's history and condition, I believe treatment with ZEPOSIA is the appropriate option for my patient. Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



UC Formulary Exception Letter

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

Name: [Patient's Name]
DOB: [XX/XX/XXXX]
Patient Policy ID Number: [Policy ID #]
Reference Number: [Reference #]
Date(s) of Service: [XX/XX/XXXX]

Re: Request for Formulary Exception for ZEPOSIA® (ozanimod)

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request coverage for ZEPOSIA® (ozanimod) for the treatment of [diagnosis], *International Classification of Diseases, 10th Revision, Clinical Modification* diagnosis code [diagnosis code]. Your reason[s] for the denial [is/are] [reason(s)].

Currently, ZEPOSIA is not on your formulary; however, I am requesting an exception for ZEPOSIA to be available as a preferred drug and ask that any applicable National Drug Code blocks be removed so a prescription for my patient may be filled.

ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration in 2021 for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is the rationale for prescribing ZEPOSIA based on my patient's disease summary.

[Insert disease summary]

I am requesting this exception because [insert reasons]. Considering the patient's history and condition, I believe treatment with ZEPOSIA is medically necessary for my patient.

Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Enclosures: [List and attach additional documents to support your treatment rationale]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



UC Letter of Appeal for Patients Not Actively on Treatment

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

Name: [Patient's Name]
DOB: [XX/XX/XXXX]
Patient Policy ID Number: [Policy ID #]
Reference Number: [Reference #]
Date(s) of Service: [XX/XX/XXXX]

Re: Letter of Appeal for ZEPOSIA® (ozanimod)

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request reconsideration of your denial of coverage for ZEPOSIA® (ozanimod) for the treatment of [diagnosis], *International Classification of Diseases, 10th Revision, Clinical Modification* (ICD-10-CM) diagnosis code [diagnosis code]. Your reason[s] for the denial [is/are] [reason(s)].

Based on my experience with treating patients with [diagnosis], ICD-10-CM diagnosis code [diagnosis code], and the patient's condition and medical history, I believe treatment with ZEPOSIA is appropriate and medically necessary. This letter provides the clinical rationale and relevant information about the patient's medical history and treatment.

ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration in 2021 for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is the rationale for prescribing ZEPOSIA based on my patient's disease summary.

[Insert disease summary]

[Supporting information as requested by the plan in the denial letter]

This is my [level of request] prior authorization appeal. A copy of the [level of denial] denial letter is included along with medical notes in response to the denial. Considering the patient's history and condition, I believe treatment with ZEPOSIA is medically necessary for my patient.

Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Enclosures: [List and attach additional documents to support your treatment rationale]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



UC Letter of Appeal for Patients Currently on Treatment

[Date]
[Health Plan Name]
ATTN: [Department]
[Medical/Pharmacy Director Name]
[Health plan address][City, State Zip]

Name: [Patient's Name]
DOB: [XX/XX/XXXX]
Patient Policy ID Number: [Policy ID #]
Reference Number: [Reference #]
Date(s) of Service: [XX/XX/XXXX]

Re: Letter of Appeal for ZEPOSIA® (ozanimod)

Dear [Medical/Pharmacy Director Name],

I am writing on behalf of [patient's name] to request reconsideration of your denial of coverage for ZEPOSIA® (ozanimod) for the treatment of [diagnosis], *International Classification of Diseases, 10th Revision, Clinical Modification* (ICD-10-CM) diagnosis code [diagnosis code]. Your reason[s] for the denial [is/are] [reason(s)].

Based on my experience with treating patients with [diagnosis], ICD-10-CM diagnosis code [diagnosis code], and the patient's condition and medical history, I believe treatment with [current drug name] should be discontinued and replaced with ZEPOSIA as it is appropriate and medically necessary. This letter provides the clinical rationale and relevant information about the patient's medical history and treatment.

ZEPOSIA is a sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration in 2021 for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

The patient is [a/an age]-year-old [male/female/other gender identification] who was diagnosed with [diagnosis] on [date]. Below is the rationale for prescribing ZEPOSIA based on my patient's disease summary.

[Insert disease summary]

[Supporting information as requested by the plan in the denial letter]

This is my [level of request] prior authorization appeal. A copy of the [level of denial] denial letter is included along with medical notes in response to the denial. Considering the patient's history and condition, I believe treatment with ZEPOSIA is medically necessary for my patient.

Please contact me at [physician's phone number] or via email at [physician's email] should you have questions or need additional information.

Thank you for your time and immediate attention to this request.

Sincerely,

[Provider name, contact information, and signature]

Enclosures: [List and attach additional documents to support your treatment rationale]

Please see page [2](#) for additional reimbursement information.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Patient Financial Support



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Patient Financial Support

Co-Pay Benefits Through ZEPOSIA 360 Support™

Prescription

- **Commercially insured patients may pay as little as \$0** in out-of-pocket costs per prescription
- Subject to a **maximum benefit** during a calendar year

Medical

- **Commercially insured patients may be reimbursed** for out-of-pocket costs associated with baseline assessments
- Subject to a **maximum benefit** during a calendar year

Note: Patients are responsible for any costs that exceed the maximum amounts.

Independent, third-party foundations

- ZEPOSIA 360 Support™ may provide information about independent third-party foundations that may be able to assist with treatment costs
- These foundations are not affiliated with BMS or any third parties who charge a fee for help with applications or medication refills
- Charitable foundations are independent from BMS and have their own eligibility and evaluation requirements
- BMS cannot guarantee that a patient will receive assistance

For complete terms and conditions, please see www.zeposia.com/terms-conditions.



Please see Important Safety Information on pages [5-7](#) and [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



Bristol Myers Squibb is committed to transparency. For information on the list price of ZEPOSIA as well as information regarding average out-of-pocket costs and assistance programs, please visit <https://www.zeposia.com/multiple-sclerosis/cost/> or <https://www.zeposia.com/ulcerative-colitis/cost/>.

CoverMyMeds is a registered trademark of CoverMyMeds LLC.

ZEPOSIA, ZEPOSIA 360 Support and ZEPOSIA logo are trademarks of Celgene Corporation, a Bristol Myers Squibb company. All other trademarks are the property of their respective owners.

© 2024 Bristol-Myers Squibb Company.

2084-US-2400695 10/24

